 | Issue navigator |
|
|
Contents of Volume 11 Suppl 5
Severe sepsis and drotrecogin alfa (activated)
Reviews
Edited by Antonio Artigas and Claude D Martin
Publication of the supplement has been sponsored by Eli Lilly & Company
|
Introduction
 
Introduction: severe sepsis and drotrecogin alfa (activated)
Antonio Artigas, Claude D Martin
Critical Care 2007, 11(Suppl 5):S1 (19 December 2007)
[Full text] [PDF] [PubMed] [Related articles]
Review
Diagnosis and treatment of severe sepsis
Yann-Erick Claessens, Jean-François Dhainaut
Critical Care 2007, 11(Suppl 5):S2 (19 December 2007)
[Full text] [PDF] [PubMed] [Related articles]
Review
Recombinant human activated protein C: current insights into its mechanism of action
Marcel Levi, Tom van der Poll
Critical Care 2007, 11(Suppl 5):S3 (19 December 2007)
[Full text] [PDF] [PubMed] [Related articles]
Review
The protein C pathway: implications for the design of the RESPOND study
Burkhard Vangerow, Andrew F Shorr, Duncan Wyncoll, Jonathan Janes, David R Nelson, Konrad Reinhart
Critical Care 2007, 11(Suppl 5):S4 (19 December 2007)
[Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]
Review
Clinical trials in severe sepsis with drotrecogin alfa (activated)
Pierre-François Laterre
Critical Care 2007, 11(Suppl 5):S5 (19 December 2007)
[Full text] [PDF] [PubMed] [Related articles]
Review
The safety profile of drotrecogin alfa (activated)
Roberto Fumagalli, Mariano A Mignini
Critical Care 2007, 11(Suppl 5):S6 (19 December 2007)
[Full text] [PDF] [PubMed] [Related articles]
Review
Practical aspects of treatment with drotrecogin alfa (activated)
Luigi Camporota, Duncan Wyncoll
Critical Care 2007, 11(Suppl 5):S7 (19 December 2007)
[Full text] [PDF] [PubMed] [Related articles]
| |
|  |
